Nevro also offers minimally invasive treatment options for patients suffering from chronic sacroiliac (SI) joint pain. SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy ...

Nevro also offers minimally invasive treatment options for patients suffering from chronic sacroiliac (SI) joint pain. SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy ...

Nevro also offers minimally invasive treatment options for patients suffering from chronic sacroiliac (SI) joint pain. SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, ...

Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss of 15 cents. The Zacks Consensus Estimate is pegged at a loss per ...

Management uses certain non-GAAP financial measures, most specifically adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the Company's operating performance period ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Nevro Corp. (NVRO) on Tuesday reported a loss of $53.1 million in its fourth quarter. The Redwood City, California-based company said it ...

Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. The company had revenue of $105.55 million for the quarter, compared to analysts’ expectations of $102.61 ...

Shares of NYSE:NVRO opened at $5.74 on Wednesday. Nevro has a 52 week low of $3.16 and a 52 week high of $15.98. The company has a current ratio of 5.02, a quick ratio of 3.76 and a debt-to-equity ...